Therapeutic Areas
At Biocon Biologics, we focus on three core therapeutic areas—Diabetes, Oncology, and Immunology—addressing some of the world’s most urgent healthcare needs. Through deep scientific expertise, world-class R&D, and a robust global infrastructure, we advance high-quality biosimilars that make essential treatments more affordable and accessible.
Our therapies help manage chronic and complex diseases for millions of patients. Building on this foundation, we are expanding our pipeline into Ophthalmology and Bone Health to further address unmet medical needs and improve health outcomes.
Our portfolio showcases the breadth of our global brands, organized by therapeutic area.
Within each area, you’ll find the molecules we develop.
Diabetes
Diabetes has become one of the most urgent health challenges of our time. Today, over 537 million adults around the world live with this chronic metabolic condition — a number expected to surge to 783 million by 2045. Diabetes is one of the most urgent health challenges of our time, affecting hundreds of millions worldwide and placing immense strain on patients, families, and healthcare systems. Despite being a century-old discovery, insulin remains out of reach for far too many who need it most.
Since 2004 when Biocon Biologics became the first company in the world to develop a biosimilar recombinant human insulin using a proprietary Pichia pastoris platform, the company has played a pivotal role for patients with diabetes, caregivers and physicians, charting a path to affordable and accessible insulin that others continue to follow.
Our expertise in pioneering affordable insulins and biosimilars has led to industry firsts—including the first interchangeable Insulin Glargine biosimilar, followed by the first and only interchangeable rapid-acting Insulin Aspart approved in the United States. Through cutting-edge science, advanced manufacturing, and strong global partnerships, we are expanding access to high-quality, affordable insulins for patients who need them most.
Oncology
Cancer touches millions of lives—one in five people will develop cancer in their lifetime, and the disease claims over 10 million lives every year, leaving a profound impact on patients, families, and communities. Beyond the physical toll, cancer brings emotional and financial challenges that few are prepared to face.
Oncology has long been a focus for Biocon Biologics. Recognizing the rising global burden of cancer, we made it our mission to prioritize this high-incidence disease and reach as many patients as possible. This commitment led to the development and launch of the first biosimilar trastuzumab, expanding access to affordable treatment options for breast cancer patients.
Today, we are redefining cancer care through science, innovation, and access. Our expanding portfolio of biosimilars brings advanced oncology therapies that are both effective and affordable to more people worldwide.
Immunology
Autoimmune diseases are on the rise worldwide, affecting millions and often leading to lifelong challenges. In the U.S. alone, nearly 50 million people live with conditions where the body’s own immune system turns against itself — a breakdown that can be both debilitating and life-threatening.
Through our deep expertise in biologics, we are developing targeted and affordable therapies that can modulate immune responses, reduce inflammation, and improve quality of life for patients living with autoimmune diseases.
Ophthalmology
Vision is one of our most vital senses — yet millions around the world are at risk of losing it due to chronic and progressive eye diseases. Conditions such as diabetic retinopathy and age-related macular degeneration (AMD) are rising sharply, driven by aging populations and increasing rates of diabetes.
At Biocon Biologics, we are committed to protecting sight and preserving quality of life. Through advanced biologics and biosimilars, we aim to make high-quality, affordable ophthalmic therapies accessible to patients globally. Our focus is on developing targeted treatments that address the underlying causes of vision loss and help patients see a clearer, brighter future.
Bone Health
Healthy bones are essential to mobility, independence, and quality of life — yet bone disorders such as osteoporosis are affecting millions worldwide, particularly among aging populations. Fragile bones increase the risk of fractures and disability, placing a growing burden on patients and healthcare systems alike.
At Biocon Biologics, we are advancing access to affordable biologic therapies that strengthen bones and restore resilience. Through our science-led innovation and deep expertise in biologics, we aim to address unmet needs in bone health — helping patients lead stronger, more active lives.
